2024
Pooled Long-Term Outcomes With Nivolumab Plus Ipilimumab or Nivolumab Alone in Patients With Advanced Melanoma.
Long G, Larkin J, Schadendorf D, Grob J, Lao C, Márquez-Rodas I, Wagstaff J, Lebbé C, Pigozzo J, Robert C, Ascierto P, Atkinson V, Postow M, Atkins M, Sznol M, Callahan M, Topalian S, Sosman J, Kotapati S, Thakkar P, Ritchings C, Pe Benito M, Re S, Soleymani S, Hodi F. Pooled Long-Term Outcomes With Nivolumab Plus Ipilimumab or Nivolumab Alone in Patients With Advanced Melanoma. Journal Of Clinical Oncology 2024, jco2400400. PMID: 39504507, DOI: 10.1200/jco.24.00400.Peer-Reviewed Original ResearchImmune checkpoint inhibitorsPatients treated with nivolumabOverall survivalNivolumab monotherapyMultivariate analysisPD-L1Advanced melanomaPD-L1 expression levelsFactors associated with decreased survivalLong-term overall survivalPresence of liver metastasesCox proportional multivariate analysisFactors associated with survivalLactate dehydrogenaseClinical factors associated with survivalPD-L1 expressionTreatment naive patientsMedian follow-upElevated lactate dehydrogenaseCompany-sponsored trialsAssociated with survivalUnresectable/metastatic melanomaCheckpoint inhibitorsOS ratesTreatment decision making
2019
Five-Year Survival and Correlates Among Patients With Advanced Melanoma, Renal Cell Carcinoma, or Non–Small Cell Lung Cancer Treated With Nivolumab
Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, Powderly JD, Sosman JA, Atkins MB, Leming PD, Spigel DR, Antonia SJ, Drilon A, Wolchok JD, Carvajal RD, McHenry MB, Hosein F, Harbison CT, Grosso JF, Sznol M. Five-Year Survival and Correlates Among Patients With Advanced Melanoma, Renal Cell Carcinoma, or Non–Small Cell Lung Cancer Treated With Nivolumab. JAMA Oncology 2019, 5: 1411-1420. PMID: 31343665, PMCID: PMC6659167, DOI: 10.1001/jamaoncol.2019.2187.Peer-Reviewed Original ResearchNon-small cell lung cancerRenal cell carcinomaLong-term survivalTreatment-related AEsOverall survivalCell lung cancerAdvanced melanomaCell carcinomaLung cancerEastern Cooperative Oncology Group performance statusFuture clinical trial developmentLong-term overall survivalActivity of nivolumabSubsequent protocol amendmentUnacceptable toxic effectsFive-year survivalOverall survival curvesPresence of liverCell death 1Clinical trial developmentUS medical centersNivolumab treatmentPerformance statusProgressive diseaseBone metastases